Retrieve available abstracts of 28 articles: HTML format
Single Articles
June 2025
SAUKKONEN J, Munsiff S, Winston C, Duarte R, et al Reply to Wilson et al.: The 4-Month HPMZ Treatment Regimen for Drug-Susceptible
Pulmonary Tuberculosis - A Word of Caution.
Am J Respir Crit Care Med. 2025. PubMed
WILSON JW, Temesgen Z MD, Gaensbauer JG The 4-Month HPMZ Treatment Regimen for Drug-Susceptible Pulmonary Tuberculosis -
A Word of Caution.
Am J Respir Crit Care Med. 2025. PubMed
MENZIES NA, Marks SM, Hsieh YL, Swartwood NA, et al Contribution of Posttuberculosis Sequelae to Life-Years Lost from Tuberculosis
Disease in the United States, 2015-2019.
Am J Respir Crit Care Med. 2025;211:1059-1068. PubMedAbstract available
March 2025
JANSSEN S, Upton C, de Jager VR, van Niekerk C, et al Telacebec, A Potent Agent in the Fight Against Tuberculosis: Findings from A
Randomized, Phase 2 Clinical Trial and Beyond.
Am J Respir Crit Care Med. 2025 Mar 21. doi: 10.1164/rccm.202408-1632. PubMedAbstract available
December 2024
DERENDINGER B, Mochizuki TK, Marcelo D, Shankar D, et al C-reactive Protein-based Screening of People with Tuberculosis Symptoms: A
Diagnostic Accuracy Study.
Am J Respir Crit Care Med. 2024 Dec 6. doi: 10.1164/rccm.202405-1000. PubMedAbstract available
November 2024
Erratum: Who Transmits Tuberculosis to Whom: A Cross-Sectional Analysis of a
Cohort Study in Lima, Peru.
Am J Respir Crit Care Med. 2024;210:1280. PubMed
August 2024
ZAVALA S, Stout JE A Balancing Act: Finding the Right Dose of Pyrazinamide to Treat Tuberculosis.
Am J Respir Crit Care Med. 2024 Aug 22. doi: 10.1164/rccm.202406-1262. PubMed
AULD SC, Barczak AK, Bishai W, Coussens AK, et al Pathogenesis of Post-Tuberculosis Lung Disease: Defining Knowledge Gaps and
Research Priorities at the 2(nd) International Post-Tuberculosis Symposium.
Am J Respir Crit Care Med. 2024 Aug 14. doi: 10.1164/rccm.202402-0374. PubMedAbstract available
ROCHE SM, Ottewill C, Mulpeter R, Brown K, et al Delayed Tuberculosis Paradoxical Reaction Associated with TNF Inhibitors.
Am J Respir Crit Care Med. 2024 Aug 12. doi: 10.1164/rccm.202402-0464. PubMed
July 2024
COHEN T, Colijn C, Warren JL Approaches for M. tuberculosis Transmission Inference Based on Genomic Data.
Am J Respir Crit Care Med. 2024 Jul 17. doi: 10.1164/rccm.202404-0835. PubMed
LEE WC Pairs or Paradoxes: Questioning Assumptions in Tuberculosis Transmission
Research.
Am J Respir Crit Care Med. 2024 Jul 17. doi: 10.1164/rccm.202405-0958. PubMed
XU AY, Velasquez GE, Zhang N, Chang VK, et al Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary
Tuberculosis: A Phase 3, Randomized, Controlled Clinical Trial.
Am J Respir Crit Care Med. 2024 Jul 16. doi: 10.1164/rccm.202401-0165. PubMedAbstract available
May 2024
DAVIES GR Reconsidering the Role of Isoniazid in Drug-resistant Tuberculosis.
Am J Respir Crit Care Med. 2024 May 1. doi: 10.1164/rccm.202403-0628. PubMed
April 2024
MATHEMA B, Burzynski J One Half of the Pair: Prioritizing Tuberculosis Transmitters for Early Detection.
Am J Respir Crit Care Med. 2024 Apr 30. doi: 10.1164/rccm.202404-0699. PubMed
DRAIN PK Another Step Closer to Genomic-informed Therapeutic Dosing for Tuberculosis
Drugs.
Am J Respir Crit Care Med. 2024 Apr 22. doi: 10.1164/rccm.202403-0566. PubMed
GAUSI K, Ignatius EH, De Jager V, Upton C, et al High-Dose Isoniazid Lacks EARLY Bactericidal Activity Against Isoniazid-resistant
Tuberculosis Mediated by katG Mutations: A Randomized, Phase 2 Clinical Trial.
Am J Respir Crit Care Med. 2024 Apr 2. doi: 10.1164/rccm.202311-2004. PubMedAbstract available
March 2024
VERMA R, Silva KED, Rockwood N, Wasmann RE, et al A Nanopore Sequencing-based Pharmacogenomic Panel to Personalize Tuberculosis
Drug Dosing.
Am J Respir Crit Care Med. 2024 Mar 5. doi: 10.1164/rccm.202309-1583. PubMedAbstract available
February 2024
TREVISI L, Brooks MB, Becerra MC, Calderon RI, et al Who Transmits Tuberculosis to Whom: A Cross-Sectional Analysis of a Cohort Study
in Lima, Peru.
Am J Respir Crit Care Med. 2024 Feb 28. doi: 10.1164/rccm.202307-1217. PubMedAbstract available
October 2023
ANIDI IU, Kirenga B, Fennelly KP Pulmonary Rehabilitation for Post-Tuberculosis Lung Disease.
Am J Respir Crit Care Med. 2023 Oct 5. doi: 10.1164/rccm.202309-1571. PubMed
ROCHESTER CL, Alison JA, Carlin B, Holland AE, et al Reply to: Pulmonary Rehabilitation for Post-Tuberculosis Lung Disease.
Am J Respir Crit Care Med. 2023 Oct 5. doi: 10.1164/rccm.202309-1714. PubMed
July 2023
OTTEWILL C, Dolan L, Lopez Bailen E, Roycroft E, et al Immunosuppressed Pets as a Conduit for Zoonotic Tuberculosis.
Am J Respir Crit Care Med. 2023 Jul 25. doi: 10.1164/rccm.202304-0734. PubMed
June 2023
PATANKAR S, Cruz AT, Douglas-Jones B, Garcia-Prats A, et al Making the Case for All-Oral, Shorter Regimens for Children with Drug-Resistant
Tuberculosis.
Am J Respir Crit Care Med. 2023 Jun 5. doi: 10.1164/rccm.202304-0670. PubMed
BRUST JCM "Weighting" the Evidence: How Much Bedaquiline Is Enough?
Am J Respir Crit Care Med. 2023;207:1423-1424. PubMed
May 2023
MITNICK CD, Nunn AJ Ascertainment Bias in TB Treatment Trials: Can Systematic Assessment of Objective
Endpoints Solve It?
Am J Respir Crit Care Med. 2023;207:1269-1270. PubMed
KURBATOVA EV, Phillips PPJ, Dorman SE, Sizemore EE, et al A Standardized Approach for Collection of Objective Data to Support Outcome
Determination for Late-Phase Tuberculosis Clinical Trials.
Am J Respir Crit Care Med. 2023;207:1376-1382. PubMedAbstract available
April 2023
BORGES DE ALMEIDA CP, Mitnick CD Intervening on Social Determinants for Better Outcomes in Pediatric Tuberculosis
Management.
Am J Respir Crit Care Med. 2023 Apr 19. doi: 10.1164/rccm.202303-0601. PubMed
MARTINEZ L, Zar HJ Reply to: Intervening on Social Determinants for Better Outcomes in Pediatric
Tuberculosis Management.
Am J Respir Crit Care Med. 2023 Apr 19. doi: 10.1164/rccm.202304-0629. PubMed
MASEKELA R, Mandalakas AM Pediatric Post-TB Lung Disease: Ready for Prime Time?
Am J Respir Crit Care Med. 2023;207:975-977. PubMed